Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 5Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Keratosis, Actinic 1

Interventions

pembrolizumab 184Carboplatin 132Cisplatin 102Paclitaxel 101Gemcitabine 86Pemetrexed 79durvalumab 75Nivolumab 67Docetaxel 55atezolizumab 51Cyclophosphamide 49Bevacizumab 49Dexamethasone 45Capecitabine 45Oxaliplatin 42130-nm albumin-bound paclitaxel 41Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 37Prednisone 32osimertinib 31olaparib 29venetoclax 28fludarabine 28Leucovorin 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × BF-200 ALA × Clear all
NCT05662202 2026-05-22

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Biofrontera Inc.

Phase 3 Active not recruiting
172 enrolled
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡